Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2a Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients With Advanced Malignancies Including Hepatocellular Carcinoma

Next Previous
Trial Profile

Phase 1/2a Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients With Advanced Malignancies Including Hepatocellular Carcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Aug 2018

At a glance

  • Drugs GNS 561 (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; First in man
  • Sponsors Genoscience

    • Most Recent Events

    • 02 May 2018 Status changed from not yet recruiting to recruiting.
    • 24 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top